CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 187 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04605991
NCT04605991Phase 3Completed
CompareCT.gov

A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring

Eli Lilly and Company·interventional·Posted Oct 28, 2020·Updated Mar 3, 2023

In Brief

A Phase 3 clinical trial evaluating LY900014 and Insulin Glargine for Type 2 Diabetes. Completed, enrolled 187 participants across 32 sites in 2 countries.

Detailed Summary

This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine. Participants will use continuous glucose monitoring (CGM) (Freestyle Libre 14-day system) during the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedOct 28, 2020
Enrollment StartNov 4, 2020
Primary CompletionFeb 4, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.7 years ago

Interventions

LY900014drug

Administered SC

Insulin Glarginedrug

Administered SC